Franklin Chu

1.6k total citations
33 papers, 1.1k citations indexed

About

Franklin Chu is a scholar working on Pulmonary and Respiratory Medicine, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, Franklin Chu has authored 33 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 15 papers in Endocrinology, Diabetes and Metabolism and 7 papers in Molecular Biology. Recurrent topics in Franklin Chu's work include Prostate Cancer Treatment and Research (23 papers), Hormonal and reproductive studies (12 papers) and Pelvic floor disorders treatments (4 papers). Franklin Chu is often cited by papers focused on Prostate Cancer Treatment and Research (23 papers), Hormonal and reproductive studies (12 papers) and Pelvic floor disorders treatments (4 papers). Franklin Chu collaborates with scholars based in United States, Norway and United Kingdom. Franklin Chu's co-authors include Robert Claude Tyler, Roger R. Dmochowski, Ramón Pérez, Martin Dineen, Richard C. Harkaway, Oliver Sartor, S. Bruce Malkowicz, Paul Sieber, John B. Forrest and K. Gary Barnette and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Franklin Chu

33 papers receiving 992 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Franklin Chu United States	19	549	326	212	169	168	33	1.1k
Tony T. Wu Taiwan	15	542 1.0×	135 0.4×	382 1.8×	327 1.9×	100 0.6×	32	1.1k
Peter Hammerer Germany	15	478 0.9×	129 0.4×	190 0.9×	176 1.0×	140 0.8×	52	868
Tzong‐Shin Tzai Taiwan	21	252 0.5×	47 0.1×	418 2.0×	253 1.5×	141 0.8×	81	1.2k
Ricardo Leão Portugal	19	440 0.8×	55 0.2×	545 2.6×	145 0.9×	116 0.7×	68	1.4k
Yasuhide Kitagawa Japan	16	292 0.5×	51 0.2×	286 1.3×	212 1.3×	42 0.3×	45	789
Masayuki Egawa Japan	14	397 0.7×	112 0.3×	326 1.5×	186 1.1×	18 0.1×	30	794
Michael A. Levesque Canada	19	336 0.6×	138 0.4×	405 1.9×	407 2.4×	19 0.1×	32	1.2k
Charles Hudd United Kingdom	8	236 0.4×	46 0.1×	262 1.2×	191 1.1×	99 0.6×	20	815
Cheol Yong Yoon South Korea	21	455 0.8×	61 0.2×	220 1.0×	125 0.7×	388 2.3×	67	1.1k
Pengfei Shen China	19	674 1.2×	37 0.1×	279 1.3×	216 1.3×	84 0.5×	96	1.1k

Countries citing papers authored by Franklin Chu

Since Specialization

Citations

This map shows the geographic impact of Franklin Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Franklin Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Franklin Chu more than expected).

Fields of papers citing papers by Franklin Chu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Franklin Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Franklin Chu. The network helps show where Franklin Chu may publish in the future.

Co-authorship network of co-authors of Franklin Chu

This figure shows the co-authorship network connecting the top 25 collaborators of Franklin Chu. A scholar is included among the top collaborators of Franklin Chu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Franklin Chu. Franklin Chu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dreicer, Robert, Franklin Chu, Robert H. Getzenberg, et al.. (2022). Phase 3 VERACITY clinical study of sabizabulin in men with metastatic castrate resistant prostate cancer who have progressed on an androgen receptor targeting agent.. Journal of Clinical Oncology. 40(6_suppl). TPS217–TPS217. 1 indexed citations

Dreicer, Robert, Franklin Chu, Robert H. Getzenberg, et al.. (2022). Phase 3 VERACITY clinical study of sabizabulin in men with metastatic castration-resistant prostate cancer who have progressed on an androgen receptor targeting agent.. Journal of Clinical Oncology. 40(16_suppl). TPS5102–TPS5102. 1 indexed citations

Taplin, Mary‐Ellen, Franklin Chu, James S. Cochran, et al.. (2016). Galeterone in treatment-naïve patients with castration-resistant prostate cancer with C-terminal androgen receptor loss: Results from ARMOR2.. Journal of Clinical Oncology. 34(15_suppl). 5064–5064. 1 indexed citations

Montgomery, Bruce, Mario A. Eisenberger, Matthew B. Rettig, et al.. (2015). Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer. Clinical Cancer Research. 22(6). 1356–1363. 64 indexed citations

Chu, Franklin, et al.. (2015). A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer. European Journal of Cancer. 51(12). 1555–1569. 11 indexed citations

Yu, Evan Y., Robert H. Getzenberg, Christopher C. Coss, et al.. (2014). Selective Estrogen Receptor Alpha Agonist GTx-758 Decreases Testosterone with Reduced Side Effects of Androgen Deprivation Therapy in Men with Advanced Prostate Cancer. European Urology. 67(2). 334–341. 16 indexed citations

Harrop, Richard, Franklin Chu, Nashat Gabrail, et al.. (2013). Vaccination of castration-resistant prostate cancer patients with TroVax (MVA–5T4) in combination with docetaxel: a randomized phase II trial. Cancer Immunology Immunotherapy. 62(9). 1511–1520. 25 indexed citations

Oh, William, Matthew D. Galsky, Walter M. Stadler, et al.. (2011). Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer. Urology. 78(3). 626–630. 59 indexed citations

Zheng, Zhong, Xinli Zhang, Hooman Khorasani, et al.. (2010). Delayed Wound Closure in Fibromodulin-Deficient Mice Is Associated with Increased TGF-β3 Signaling. Journal of Investigative Dermatology. 131(3). 769–778. 56 indexed citations

10.

Chu, Franklin, Joel Picus, Paula M. Fracasso, et al.. (2010). A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human αv integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Investigational New Drugs. 29(4). 674–679. 25 indexed citations

11.

Chu, Franklin, Neila Smith, & Takeshi Uchida. (2009). Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Current Therapeutic Research. 70(6). 405–420. 26 indexed citations

12.

Smith, Matthew R., S. Bruce Malkowicz, Franklin Chu, et al.. (2008). Toremifene Improves Lipid Profiles in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase III Study. Journal of Clinical Oncology. 26(11). 1824–1829. 61 indexed citations

13.

Smith, Matthew R., S. Bruce Malkowicz, Franklin Chu, et al.. (2007). Toremifene Increases Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase 3 Clinical Study. The Journal of Urology. 179(1). 152–155. 89 indexed citations

14.

Chu, Franklin, et al.. (2006). Management of Overactive Bladder and Urge Urinary Incontinence in the Elderly Patient. The American Journal of Medicine. 119(3). 29–36. 52 indexed citations

15.

Chu, Franklin & Roger R. Dmochowski. (2006). Pathophysiology of Overactive Bladder. The American Journal of Medicine. 119(3). 3–8. 67 indexed citations

16.

Lavelle, John P., Mickey M. Karram, Franklin Chu, et al.. (2006). Management of Incontinence for Family Practice Physicians. The American Journal of Medicine. 119(3). 37–40. 6 indexed citations

17.

Chu, Franklin, Roger R. Dmochowski, Daniel Lama, Rodney U. Anderson, & Peter K. Sand. (2005). Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: A subanalysis of data from the OPERA trial. American Journal of Obstetrics and Gynecology. 192(6). 1849–1854. 26 indexed citations

18.

Sartor, Oliver, et al.. (2003). An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer. Urology. 62(2). 319–323. 37 indexed citations

19.

Chu, Franklin, et al.. (2002). A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clinical Therapeutics. 24(11). 1902–1914. 71 indexed citations

20.

Chu, Franklin, et al.. (2002). A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer.. PubMed. 168(3). 1199–203. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact